Control of haemorrhage in haemophilia A. All plasma fractions should comply with the WHO Requirements for the Collection, Processing and Quality Control of Blood, Blood Components and Plasma Derivatives (Revised 1992). WHO Expert Committee on Biological Standardization Forty-third report, WHO Technical Report Series, No. 840, 1994, Annex 2.

Added to list 1979.

Square box to accommodate cryoprecipitate.

Specific expertise, diagnostic precision, individualization of dosage or special equipment required for proper use.

The use of alternative treatment, in the form of cryoprecipitate or fresh frozen plasma is less effective and less safe.

Plasma fractions should comply with the WHO Requirements for the Collection, Processing and Quality Control of Blood, Blood Components and Plasma Derivatives (Revised 1992). WHO Technical Report Series, No. 840, 1994, Annex 2

Factor VIII concentrate is a complementary preparation and a representative coagulation factor preparation. Various preparations can serve as alternatives

Uses: control of haemorrhage in haemophilia A

Precautions: intravascular haemolysis after large or frequently repeated doses in patients with blood groups A, B, or AB (less likely with high potency, highly purified concentrates)

Dose: Haemophilia A, by slow intravenous infusion, ADULT and CHILD according to patient’s needs

Adverse effects: allergic reactions including chills, fever